SCHEMBL4926862

SCHEMBL4926862

CCCN1Cc2nc3c(-c4cc(Cl)ccc4OC)cccc3c(N)c2C1=O

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 4/20 0.41
▸ TP53 P04637 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ GABRG2 P18507 9/20 0.39
▸ GABRB3 P28472 9/20 0.39
▸ GABRA2 P47869 9/20 0.39
▸ GABRA1 P14867 1/20 0.39
▸ GABRA5 P31644 1/20 0.39
▸ GABRA3 P34903 1/20 0.39
▸ CRHR1 P34998 1/20 0.38
▸ HRH4 Q9H3N8 1/20 0.36
▸ RECQL P46063 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2661536 0.90 GABRG2 (0.49) PDE5ATP53GABRG2GABRB3GABRA2
SCHEMBL4916122 0.89 GABRG2 (0.39) PDE5ATP53GABRG2GABRB3GABRA2
SCHEMBL2660719 0.89 CRHR1 (0.36) PDE5ALMNACRHR1KDM4EALDH1A1
SCHEMBL2661856 0.86 GABRG2 (0.38) PDE5ATP53GABRG2GABRB3GABRA2
SCHEMBL2661448 0.86 GABRG2 (0.37) PDE5ATP53MEN1LMNAKMT2A
SCHEMBL4921086 0.85 CNR2 (0.37) PDE5ATP53LMNAKMT2AGABRG2
SCHEMBL4924170 0.85 TP53 (0.42) PDE5ATP53MEN1LMNAKMT2A
SCHEMBL4922653 0.85 GABRG2 (0.49) PDE5ATP53MEN1LMNAKMT2A
SCHEMBL4922963 0.85 TLR8 (0.40) PDE5ATP53LMNAGABRG2GABRB3
SCHEMBL4913419 0.85 GABRG2 (0.39) PDE5ATP53LMNAGABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF PDE5A 742/4885TP53 1103/4885MEN1 1506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback